INTRODUCTION {#S1}
============

It is increasingly appreciated that the diversity of clinical outcomes in HNSCC is likely a reflection of the molecular heterogeneity of the tumor population^[@R1],[@R2],[@R3]^. Previous studies have led to the identification of a variety of genes and other molecular features for stratifying HNSCC tumors, such as efforts to cluster gene expression profiles to define subtypes^[@R4],[@R5],[@R6],[@R7],[@R8]^. To comprehensively define this heterogeneity of common tumor types including HNSCC, The Cancer Genome Atlas (TCGA) project has generated multi-tiered molecular profiles for over 7000 patient tumors, providing an unprecedented opportunity to study the complex interrelations among fundamentally different types of molecular events and clinical outcomes such as patient survival.

Here we have built on the infrastructure established by TCGA to systematically and transparently unravel these complex relationships for HNSCC. To this effect, we obtained all available molecular and clinical data from TCGA (unpublished, TCGA HNSCC working group) as of the January 15, 2014 Firehose run and have documented all data-processing and analysis in a series of IPython Notebooks^[@R9]^ (**Methods**, **[Supplementary Table 1](#SD2){ref-type="supplementary-material"}**). Five tiers of data -- somatic mutations, chromosomal aberrations, mRNA expression, microRNA expression, and clinical variables -- were analyzed for a total of 378 HNSCC patients resulting in measurements of over 34,000 molecular or clinical values for each patient (**[Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}**). Because old age and HPV status are associated with distinct molecular profiles and clinical outcomes^[@R1]^ (**[Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}**), we focused analysis on the 250 patients under 85 years of age with HPV-- tumors and complete molecular profiles.

RESULTS {#S2}
=======

Identification of prognostic events in HNSCC {#S3}
--------------------------------------------

We first sought to distill this multi-tiered, genome-wide dataset into a set of informative molecular and clinical events with potential relevance to cancer. First, individual somatic mutations and mRNA expression levels were integrated with knowledge of human molecular pathways to define aggregate 'pathway-level events' (**[Supplementary Fig. 1b-e](#SD1){ref-type="supplementary-material"}, Methods**). Second, both individual and pathway events were filtered to select those that occur at high frequency (somatic mutations, chromosomal aberrations) or differential expression (mRNA and microRNA levels) in tumor versus normal tissue. The result of this analysis was a pool of 878 total events combined over all five tiers of data (**[Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}**).

Next, we screened for individual events within each data type that are strongly predictive of survival, identifying 82 prognostic events out of the 878 (**[Fig. 1a](#F1){ref-type="fig"}**, **[Supplementary Table 2](#SD2){ref-type="supplementary-material"}**). Among somatic mutation events, *TP53* mutation was most strongly predictive overall, resulting in poor prognosis (Hazard Ratio 2.9 ±0.8, Benjamini Hochberg corrected *P* \< 0.01). As has been observed previously, survival outcomes were dependent on the TP53 protein domain affected by the mutation or its predicted functional status^[@R10]^ (**[Fig. 1b](#F1){ref-type="fig"}**). However, we found that patients with mutations predicted as non-disruptive of function nonetheless had worse prognosis than patients with wild-type *TP53* (Hazard Ratio 2.2±0.7, *P* = 0.03). Among copy-number alterations, the most significant survival association was with heterozygous chromosomal deletions on the 3p arm which also led to very poor prognosis (**[Fig. 1a](#F1){ref-type="fig"}**, Hazard Ratio 3.5±1.1, Benjamini Hochberg corrected *P* = 0.002). Further analysis of chromosome 3p revealed that many patients have a deletion spanning a large fraction of the arm with increasing frequency of deletion approaching a fragile site in the 3p14.2 region^[@R11]^ (**[Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}**). Although general chromosomal instability (CIN) as well as deletion of many individual chromosomal regions have previously been implicated as diagnostic^[@R1],[@R12]^ and prognostic^[@R7],[@R13],[@R14],[@R15]^ markers, we find that the 3p event in particular was responsible for the majority of the impact on survival when compared with global rates of gene deletion (**[Fig. 1c](#F1){ref-type="fig"}**).

*TP53* and 3p events co-occur and their combination predicts worse clinical outcome {#S4}
-----------------------------------------------------------------------------------

It has previously been shown that genetic alterations often act by redundant or synergistic mechanisms to confer a growth advantage in the tumor^[@R16],[@R17]^. Under the hypothesis that individual events might act in concert, we next examined the 82 prognostic events for pairwise association across the patient cohort. This analysis identified 33 pairs of events that were significantly cooccurring or mutually exclusive (**[Supplementary Table 3](#SD2){ref-type="supplementary-material"}**). Among these, a particularly striking finding was that mutation of *TP53* and deletion of 3p occur very frequently together, in 179 of 250 HPV-- tumors (**[Table 1](#T1){ref-type="table"}, [Fig. 1d](#F1){ref-type="fig"}**). While mutation of *TP53* has previously been associated with chromosomal instability^[@R1]^, we found that *TP53* mutation associates with 3p loss far more frequently than it does with deletions in other chromosomal regions (**[Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}, [Supplementary Tables 4-6](#SD2){ref-type="supplementary-material"}**). Moreover, the combination of *TP53* and 3p events led to significantly worse survival than was predicted by either event independently or additively. Thus the synergistic interaction between *TP53* and 3p, with respect to both co-occurrence and survival, supports a clear molecular stratification of HNSCC tumors with and without this combination of events ([Fig. 1c-e](#F1){ref-type="fig"}, Methods, [Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}, [Supplementary Table 7](#SD2){ref-type="supplementary-material"}).

We found that the *TP53*-3p combination of events is associated with advanced tumor stage, although the stratification remains prognostic at all stages (**[Supplementary Figure 6](#SD1){ref-type="supplementary-material"}**). Furthermore, the prognostic effect cannot be explained by clinical covariates alone and is particularly strong for smokers under 75 years old (175 patients, the majority of the TCGA cohort) for which the hazard ratio was 5.1 for the *TP53*-3p event relative to patients without this combination (**[Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}, Methods**).

To explore whether the interaction between *TP53* mutation and 3p deletion could be replicated in new patients, we obtained 126 additional HNSCC HPV-- samples that had been deposited in TCGA while our initial study was underway (not included in the January 15, 2014 Firehose run). While these new patients did not yet have sufficient clinical follow-up for survival analysis, we indeed observed the same high co-occurrence of *TP53* mutation and 3p deletion (**[Table 1](#T1){ref-type="table"}**).

We also analyzed clinical follow-up data for 48 HNSCC HPV-- tumors from the University of Pittsburgh Medical Center^[@R3]^ for which the exome sequencing and copy number profiles had been previously collected after surgery (UPMC cohort, **[Supplementary Table 1](#SD2){ref-type="supplementary-material"}**). We observed that in this cohort, patients whose tumors contain the *TP53*-3p aggregate event have substantially worse prognosis than patients with *TP53* mutation alone, confirming the very large effect seen in the TCGA population (**[Fig. 2a](#F2){ref-type="fig"}** and **[Table 1](#T1){ref-type="table"}**). *TP53* and 3p events also co-occurred in the UPMC cohort, although with a lower effect size than in the two TCGA cohorts (**[Table 1](#T1){ref-type="table"}**); we suspect this is due to the much higher error rate of DNA sequencing in the earlier UPMC study, resulting in false-negative mutation calls (**Methods**).

We also sought evidence for the *TP53*-3p combination in patients with HPV+ tumors, in which TP53 is inactivated via interaction with HPV viral proteins^[@R18],[@R19]^. Analysis of 59 HPV+ tumors from the TCGA and UPMC cohorts showed that *TP53* mutation is very rare in the presence of HPV (Odds Ratio 0.01, *P* = 10^−27^ by Fisher\'s Exact Test), consistent with the expectation that the mutation confers little selective advantage once TP53 is inactivated by HPV. Among HPV+ tumors, the 25 tumors with 3p deletion had significantly worse prognosis than the 34 without the 3p event (Hazard Ratio 5.5 ± 2.6, *P* = 0.004). This finding lends further support for interaction between *TP53* and chromosome 3p with respect to survival and stratifies the growing population of patients with HPV+ tumors^[@R19]^ (**[Fig. 2b](#F2){ref-type="fig"}**).

Another question was whether the *TP53*-3p interaction is specific to HNSCC or has broader support across diverse tissues. For this purpose, we performed a pan-cancer analysis based on all publicly available molecular data in TCGA (excluding HNSCC patients), covering 4404 patients over an additional 17 cancer types^[@R20]^ (**Methods**). Although these tissues are molecularly heterogeneous and present with different patient outcomes (**[Supplementary Fig. 8a-c](#SD1){ref-type="supplementary-material"}**), we nonetheless found compelling evidence for both the co-occurrence and impact on survival of *TP53* mutation and 3p deletion in this broader cohort, even when tissue type, patient age, and staging are accounted for (**[Fig. 2c-d](#F2){ref-type="fig"}**, **[Table 1](#T1){ref-type="table"}**).

Characterization of subtypes defined by combined *TP53*-3p event {#S5}
----------------------------------------------------------------

Finally, we investigated whether the major subtypes defined by *TP53* and 3p status (**[Fig. 1e](#F1){ref-type="fig"}**) could be subdivided further by additional molecular markers (**Methods**). Indeed, we found that the 179 patients with the combined *TP53*-3p event were well stratified by the additional presence of microRNA mir-548k (**[Fig. 3a](#F3){ref-type="fig"}, [Supplementary Fig. 7c](#SD1){ref-type="supplementary-material"}**) or mutation of the *MUC5B* gene (**[Fig. 3b](#F3){ref-type="fig"}, [Supplementary Fig. 7d](#SD1){ref-type="supplementary-material"}**), both of which were associated with worse prognosis. Mir-548k is near *CCND1* and *FADD* on 11q13.3, which is commonly amplified in HNSCC^[@R14]^. Very recently, this micro-RNA has been shown to have oncogenic behavior in Oesophegeal Squamous Cell Carcinoma cell lines^[@R21]^. While we found that 11q13.3 amplification is associated with survival to a lesser degree than mir-548k expression, the prognostic effect seems to be specific to the expression of the micro-RNA (**[Fig. 3c](#F3){ref-type="fig"}**, **[Supplementary Fig. 9](#SD1){ref-type="supplementary-material"}**).

Among patients lacking the *TP53*-3p event combination, we found strong enrichment for mutations to Caspase 8 as well as Ras and components of Ras signaling (**[Table 2](#T2){ref-type="table"}**, **[Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}**). These enrichments were replicated in the TCGA molecular validation cohort (**[Table 2](#T2){ref-type="table"}**). The mutual exclusivity of Caspase 8 or Ras with *TP53-*3p provides further support for a *TP53*-3p defined subtype, and it implicates alternative routes to tumor progression in the absence of the *TP53*-3p event.

DISCUSSION {#S6}
==========

As we approach a full inventory of driver events in cancer^[@R22]^, a key next step is to map and decode the complex network of interactions among individual events. Here, such an analysis was performed to identify a definitive stratification of head and neck cancer based on the largest tissue bank and dataset in existence. We have shown that *TP53* mutation, a well-studied driver event which leads to poor patient survival, is nearly always accompanied by specific loss of chromosome 3p (**[Fig. 1d](#F1){ref-type="fig"}**, **[Table 1](#T1){ref-type="table"}**). As has been argued for other cancer mutations^[@R17],[@R23]^, the frequent co-occurrence of *TP53* and 3p alteration implies a selective advantage of cells acquiring both genomic events. In this study, the detection of the *TP53*-3p interaction was possible due to the high prevalence of each event individually, and their high (marginal) associations with patient survival.

While our study focused almost entirely on a single compelling interaction, our full analysis uncovered an additional 32 interactions in HNSCC which remain to be investigated (**[Supplementary Table 3](#SD2){ref-type="supplementary-material"}**). It is likely that this number is an underestimate, as low frequency and/or non-prognostic events were not evaluated. As cancer cohorts become larger, analyses such as this will become more powered, creating the opportunity to re-evaluate the cancer landscape from the perspective of pairwise and ultimately higher-order interactions among events.

Our analysis identifies two distinct clinical and molecular paths to cancer in HPV-- HNSCC patients. The first group, characterized by *TP53* mutation and loss of the 3p chromosome, is associated with advanced clinical stage and common risk factors such as smoking. Nonetheless, this group tends to have very poor outcomes even when evaluated independently of these risk factors (**[Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}**). The second group of patients, lacking the *TP53*-3p combination of events, is characterized by mutations to RAS signaling and Caspase 8 (**[Table 2](#T2){ref-type="table"}**) and, ultimately, less aggressive tumors.

Further study is clearly warranted to elucidate the molecular underpinnings of these two groups of patients, with the goal of using such molecular stratification alongside clinical variables to inform patient treatment. Open questions relate to mechanism and the ordering of *TP53* and 3p events. What is the factor or factors encoded on chromosome 3p that are responsible for the interaction with *TP53*? Does one event necessarily precede the other and is a particular order required for poor survival? It is plausible that genomic instability primed by *TP53* mutation gives rise to loss of activity of a key factor encoded on chromosome 3p, but other scenarios are possible. Regardless, since the interaction of 3p with *TP53* or HPV status is independent of tumor stage, treatment of HNSCC patients might be modified to coincide with this specific molecular classification. In HPV-- HNSCC, the need for patient-tailored treatment programs is especially great, as we are currently in an era where we have maximized toxicity of existing regimens without necessarily improving outcome in cancers.

Our results also underscore the importance and value of public efforts such as TCGA in gathering, organizing, and distributing genomic data. Our work builds on the exemplary TCGA data collection and analysis pipeline^[@R20]^ to integrate data across different measurement platforms, with the goal of finding higher-order interactions of molecular events. Following the example of TCGA, we have documented and made public all analyses conducted in this study, ranging from data download to processing, exploratory analyses, statistical modeling, and visualization (**Methods**). With such a large and complex dataset, transparency and reproducibility of analysis is essential to provide a clear understanding of the methodology and to allow for further mining of results and extension to new datasets.

ONLINE METHODS {#S7}
==============

1. Availability {#S8}
---------------

All data-retrieval and processing steps are documented in a series of IPython notebooks^[@R9]^ available along with source code online at (<https://github.com/theandygross/TCGA>). These notebooks provide fully executable instructions for reproduction of the analyses and generation of figures and statistics for this study.

2. Molecular Data {#S9}
-----------------

Data were obtained from The Cancer Genome Atlas Genome Data Analysis Center (GDAC) Firehose website (<https://confluence.broadinstitute.org/display/GDAC/>) using the firehose_get data-retrieval utility. All data were downloaded from the January 15th, 2014 standard data and analyses run unless otherwise specified. In order to maintain coherency of the analysis across different data layers and cancer types, we used Level 3 normalized molecular data as the input to our analysis. The use of the GDAC pipeline is intended to make these results easy to update as more TCGA data become available.

For a number of pan-cancer samples we generated mutation calls from TCGA aligned BAM files obtained from the UCSC Cancer Genomics Hub (<https://cghub.ucsc.edu/>). These calls were only used for patients with sequenced exome data that have yet go through the Firehose processing pipeline. Somatic mutation calls were made by running the MuTect mutation calling program^[@R24]^ and the Genome Analysis Toolkit (GATK) SomaticIndelDetector^[@R25]^ function on targeted regions with default parameters. All steps for downloading and processing this data are documented in the analysis notebooks and accompanying software repository. All mutation calls generated for this analysis are included as **[Supplementary Table 8](#SD2){ref-type="supplementary-material"}**. While these calls have yet to go through manual curation, we benchmarked this pipeline against TCGA working group mutation calls and found very high overlap with 94% sensitivity and 96% specificity.

3. Pathway Data {#S10}
---------------

Pathway data were downloaded from the Molecular Signatures Database^[@R26]^ (mSigDB). Version 3 of the canonical pathway gene-sets was used for this analysis.

4. Candidate biomarker construction {#S11}
-----------------------------------

Mutation calls were extracted from the annotated MAF files obtained from the Firehose and filtered to include only non-silent mutations. Each patient was associated with a binary vector in which each position represents a gene; the position is set to 1 if the gene is observed to harbor one or more mutations in the patient and set to 0 otherwise. Mutation meta-markers were constructed by collapsing genes within a pathway gene-set via a logical OR such that the pathway is considered altered in a patient if any of its genes have a mutation (**[Supplementary Fig. 1b-c](#SD1){ref-type="supplementary-material"}**). Pathway markers that were characterized by a single highly mutated gene or were highly correlated with mutation rate (Mann-Whitney U test, *P* \< .01) were filtered.

Copy-number aberrations were extracted from the GISTIC2^[@R27]^ processing pipeline included in the standard Firehose analysis run. For biomarker construction data aggregated on significantly altered lesions (as deemed significant at the default 99% confidence settings) were used.

mRNA and miRNA expression data were obtained from the Level 3 normalized gene-by-patient matrices generated as part of the Firehose analysis pipeline. Data were log~2~ transformed. Genes/ miRNAs were first filtered based on differential expression comparing the full set of tumor expression profiles with the 34 profiles available for matched normal tissue (t-test, cutoff at *P* \< .01). A pattern of background expression was estimated by taking the first principal component of non-differentially expressed genes or miRNAs. This background signal is meant to approximate the most common non-tumor related variation in expression due to inherent properties of the cohort such as population substructure or tissue specific expression changes. Real valued features with high correlation (Pearson Correlation, *P* \< 10^−5^) to this background expression pattern were filtered. For the survival analysis, only the top 300 (of a possible 20502) differentially expressed genes were included in the analysis to limit the burden of multiple hypothesis correction (all 251 differentially expressed miRNA were used).

Markers used in this analysis consisted of binary markers and continuous valued markers. Binary markers were used when expression was only present (having more than ½ read per million) in a moderate fraction of the cohort (between 20 patients and half of the cohort). Real valued gene and miRNA expression levels were used for differentially expressed features not assigned as binary markers. Gene expression meta-markers were constructed from the loading of the first principal component of the reduced gene-by-patient matrix defined by each gene set. Due to similarity of gene-sets causing redundant gene expression meta-markers, marker pairs with high correlation (Spearman rho \> .7) were reduced to a single informative marker by choosing the marker with the greatest differential expression. For the survival analysis, continuous valued markers were transformed into binary events prior to testing by setting a threshold that minimized the difference in variance between the resulting two groups. This was used to capture the skew of the distribution and assign the patients on the tail of the expression distribution as having an expression event (**[Supplementary Fig. 1e](#SD1){ref-type="supplementary-material"}**).

5. Clinical Data {#S12}
----------------

Clinical data were downloaded directly from the TCGA Data Portal (<https://tcga-data.nci.nih.gov/tcga/>). All outcomes reported relate to all-cause survival. Survival times were censored after five years to reduce the confounding effect of patient age. For **[Fig. 2d](#F2){ref-type="fig"}**, survival times were censored after three years to show the specific effect within this time window, but all other figures and all statistics cited in the paper use five-year survival. While data on comorbidity is limited for this cohort, from other studies we can estimate the competing mortality within this time-frame to be about 20%^[@R28],[@R29]^. We expect the actual effect of such confounding to be minimal as separation in the survival curves that we observe generally occurs within the first two years, during which time we expect non-cancer associated death rates to be much lower.

For the primary and secondary survival screens, clinical data with missing data were used but statistics were only calculated on patients with data reported. In multivariate analysis (**[Supplementary Figure 7](#SD1){ref-type="supplementary-material"}**) missing value indicators were used.

6. HPV Status {#S13}
-------------

HPV calls from sequencing data were obtained from the TCGA HNSCC analysis working group. Due to the incompleteness of this dataset, this information was supplemented with HPV status called from a PCR-based MassArray Assay diagnostic provided on the TCGA data portal for patients where sequence-based data were not available.

7. Prioritization of Prognostic Events {#S14}
--------------------------------------

Feature selection is preformed prior to prognostic event prioritization. Events are selected for which at least 5% of patients are assigned to each group.

Prognostic events (**[Fig. 1a](#F1){ref-type="fig"}**) are prioritized via a likelihood ratio test comparing a Cox-proportional hazards model^[@R30]^ fit with a candidate biomarker and covariates against a null model fit with the covariates alone. Age and the binary variable patient age \> 75 are used as covariates (both age variables are used to model a non-linear association of patient age with survival). A multiple-hypothesis testing correction is employed which uses the method of Benjamini and Hochberg^[@R31]^ to control for the false discovery rate across the entire pooled space of tested features. After multivariate testing, a univariate log-rank test is assessed for each event and features with high multivariate significance, but low univariate significance (*P* \< 0.05) are filtered from the pool of prognostic events.

As discussed in the text and in **[Figure 3](#F3){ref-type="fig"}**, we conducted a second prognostic screen within the 179 patients with the *TP53*-3p aggregate event. For this analysis feature construction was repeated, resulting in 1008 candidate biomarkers (note that this number was higher than the primary screen due to more events passing the 5% threshold). During this secondary screen, we found the patient year of diagnosis to have a large impact on outcomes. For this reason we included this variable as a covariate in this screen.

8. Statistical Analysis of *TP53*-3p Interaction on Survival {#S15}
------------------------------------------------------------

To asses the role of an interaction term in a statistical model of patient outcomes we performed leave-one-out cross-validation on a logistic regression model as shown in **[Supplementary Figure 5](#SD1){ref-type="supplementary-material"}**. To convert the survival data into a binary classification problem, we organized patients into two classes depending on whether they were surviving or deceased at T years after surgery. In this analysis, the ratio of deceased to surviving patients is artificially high due to the ability to observe a death in a shorter followup than the full time interval required to annotate a patient as surviving (i.e. the basis of the Cox censorship problem). To reduce this bias, we removed patients with an observed death but a time of surgery after a set year (2013 -- (T -- 1)). As the problem was often unbalanced (the number of surviving patients differed from the number of deceased), re-weighting was preformed to give both classes equal weight. A multivariate Cox model fit to the most significant model is also shown in **[Supplementary Table 7](#SD2){ref-type="supplementary-material"}**.

9. University of Pittsburg Medical Center Cohort {#S16}
------------------------------------------------

3p chromosomal status was estimated via the median copy number of the twelve genes on the 3p14.2 locus. Matched exome and copy-number data were available for 48 / 63 patients with HPV-- tumors. In preliminary analysis we found the UPMC cohort to have a significantly lower overall mutation rate than the TCGA cohort, with a median of 73 mutations per patient as compared to 104 mutations per patient in TCGA (Mann-Whitney U test, *P* \< .001). This can likely be attributed lower depth of coverage and/or less sophisticated variant calling techniques as the UPMC study was one of the first large whole exome molecular cohorts and predates the TCGA data collection by about two years.

10. Pan-cancer Analysis {#S17}
-----------------------

Pan-cancer data were downloaded and processed in the same manner as the HNSCC cohort. 3p chromosomal status was estimated via the median copy number of the twelve genes on the 3p14.2 locus.

In order to limit the heterogeneity of the pan-cancer cohort such that differences in molecular characteristics could be assessed, we performed a number of pre-processing steps. This reduced the patient cohort from 7081 to 4404 patients appropriate for survival analysis through the following filters: "Only primary tumors were used for all patients, metastatic tumors were discarded. Glioblastoma patients were excluded due to the extremely low survival rate (6% five year survival)." "Diffuse large b-cell lymphoma, kidney chromophobe, thyroid carcinoma, and prostate adenocarcinoma patients were removed due to extremely high rates of survival in the cohorts (84%, 86%, 90%, and 96% five year survival)." "Adrenocortical carcinoma, esophageal carcinoma, and pancreatic adenocarcinoma were excluded due to low sample counts (14, 39, and 69 patients in each tissue, respectively). Patients older than 85 years of age were excluded from the analysis to limit confounding from age (115 patients, Hazard ratio = 2.2 ± 3)." "Patients with high levels of residual tumor were excluded (66 patients, Hazard ratio = 2.9 ± .5)." "Stage IV patients were excluded (612 patients, Hazard ratio = 2.0 +/- .1)" "To limit circularity, HNSCC patients were excluded from all pan-cancer calculations but remain **[Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}** to allow for comparison to other tissue types."
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![Prognostic effects and co-occurrence of *TP53* and 3p\
**a**, Five-year survival (error bars indicate 95% CI) for the most significant events of each category (colors). Numbers above bars represent number of patients with each event. **b**, Comparison of 5-year survival for patients with different types of non-silent *TP53* mutations verses wild-type patients. L2 and L3 represent TP53 binding domains. Numbers in parentheses represent number of patients with a given mutation, patients with multiple *TP53* mutations are represented multiple times in this plot. P-value represents log-rank test for *TP53* mutation types excluding wild type. **c,** Hazard ratios for multivariate Cox model fit with 3p deletion and global deletion rate (CIN) across different patient sets (age covariate not shown, error bars indicate 95% CI, p-values represent significance of likelihood ratio test for model fit with and without 3p deletion). **d**, Venn diagram showing co-occurrence of *TP53* mutation and deletions on the 3p chromosome. **e**, Kaplan-Meyer curves showing survival outcome for all combinations of 3p deletion and *TP53* mutation events (colors correspond to patient subsets in panel **d**).](nihms-612904-f0001){#F1}

![Replication of *TP53*-3p association\
**a**, Survival comparison of patients with *TP53*-3p aggregate event versus those with only *TP53* mutation in the independent UPMC cohort. **b**, Loss of 3p chromosomal arm is associated with lower survival in patients with HPV+ tumors (TCGA and independent cohorts). **c,** Assessment of 3p loss and *TP53* mutation association in TCGA Pan-Cancer cohort (HNSCC excluded). **d**, Corresponding hazard ratio for multivariate model of three-year truncated survival (shown by dotted line in panel **c**) when controlling for tissue type, age, and stage covariates. Error bars indicate 95% confidence.](nihms-612904-f0002){#F2}

![Characterization of molecular subtypes defined by the *TP53*-3p aggregate event\
Patients with the *TP53*-3p aggregate event can be further stratified by the presence of **a**, mir-548k or **b**, *MUC5B*. **c**, Frequency of high gain amplification (top panel) and association with patient survival for gene / miRNA expression (bottom panel) along the 11q13 chromosomal segment. P-values in **a** and **b** are Benjamini-Hochberg-corrected for 1008 events a secondary prognostic biomarker screen (Methods). All survival associations are calculated by a likelihood ratio test with age and year of diagnosis used as covariates in the set of 179 patients with the *TP53*-3p event (*TP53*-3p negative curves shown for comparison, but not used in computation).](nihms-612904-f0003){#F3}

###### 

Co-occurrence and survival interaction of *TP53* and 3p events.

                                        Co-occurrence of *TP53* / 3p events   Survival Interaction *TP53*-3p versus *TP53*         
  ----------------- ------------ ------ ------------------------------------- ---------------------------------------------- ----- -------
  **TCGA**          Discovery    250    6.6                                   10^--4[\*](#TFN1){ref-type="table-fn"}^        5.6   0.001
  **Recent TCGA**   Validation   126    10                                    10^--6^                                        ND    ND
  **UPMC**          Validation   48     2.5                                   0.2                                            6.3   0.01
  **Pan Cancer**    Validation   4404   2.0                                   10^--25^                                       1.4   0.002

Bonferroni corrected for test space

Univariate model in patients under 75 years of age only

###### 

Co-occurrence of *TP53*-3p aggregate event and gene mutations.

                                              Co-occurrence of *TP53*-3p event and *CASP8* mutation   Co-occurrence of *TP53*-3p event and *RAS* Signaling Pathway^[†](#TFN3){ref-type="table-fn"}^ mutation                                                             
  ------------------------ ------------ ----- ------------------------------------------------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------- ---- ------ ---------------------------------------------
  **TCGA**                 Discovery    250   21                                                      0.13                                                                                                     3 × 10^--3[\*](#TFN4){ref-type="table-fn"}^   23   0.11   3 × 10^--4[\*](#TFN4){ref-type="table-fn"}^
      *TP53*-3p positive                179   6                                                                                                                                                                                                              6           
      *TP53*-3p negative                71    15                                                                                                                                                                                                             17          
  **Recent TCGA**          Validation   126   20                                                      0.038                                                                                                    7 × 10^--8^                                   21   0.86   5 × 10^--6^
      *TP53*-3p positive                81    2                                                                                                                                                                                                              4           
      *TP53*-3p negative                45    18                                                                                                                                                                                                             17          

Biocarta SOS1 Mediated RAS Signaling Pathway (Reacome 524)

Bonferroni corrected for test space of 121 gene and pathway mutation events
